The cobas EGFR Mutation
Test v2 is intended to be used as an aid in the identification of NSCLC patients for whom treatment with Tarceva (erlotinib), in first-line therapy, and TAGRISSO(TM) (osimertinib) in second and subsequent lines of therapy, may be effective.
The impact of each mutation
on patients' health was assessed by first examining data on the salt concentrations in the sweat of patients bearing each particular mutation
Conclusion: MPL W515L/K mutations
may be helpful for identifying clonal disease in MPN patients with no established Ph chromosome or JAK-2 V6171 mutation
Researchers analyzed data from 964 patients, noting their mutation
status and aspirin intake after diagnosis.
The cumulative 10-year risk of developing contralateral breast cancer (CBC) was 6% in women with no BRCA mutations
, 11% with a BRCA2 mutation
, and 20% in those with a BRCAl mutation
While lower than the 5- to 20-fold increase in risk for carriers of the mutation
, this rate would still be high enough to warrant breast cancer surveillance.
According to researchers, current drugs do not target IHD1, so patients with this mutation
may respond differently to the drugs that are now used.
Intended as a research tool, the T790M quantitative mutation
assay detects the presence of a mutant thymidine base in a background of normal cytosine bases at position 2369 of the EGFR gene.
2003) found a compound heterozygous mutation
in three patients from one family inherited from both heterozygous parents.
The LightCycler PCR method was standardized with use of DNA samples of Greek origin from 100 [beta]-thalassemia heterozygotes with [beta]-thalassemia mutations
characterized previously by direct mutation
assays (1, 8).
The odds of breast cancer in women with a BRCA1 mutation
also increased with the time elapsed since discontinuation of oral contraceptive use.
analysis in 600 French cystic fibrosis patients.
Just because they have a genetic mutation
doesn't mean they're going to die.
ChemGenex is currently conducting a Phase 2/3 registration-directed study evaluating the use of Ceflatonin([R]) in CML patients who have the T315I Bcr-Abl point mutation
that is associated with resistance to imatinib and other tyrosine kinase inhibitors.
He eventually learned that he has a genetic mutation
called Delta 32--a "defective" genotype that prevents his being infected by HIV-1, the most common strain of HIV.